Elicio Therapeutics, Inc.
ELTX
$8.05
$0.516.76%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 46.48% | -46.09% | 5.23% | -56.49% | -76.72% |
| Total Depreciation and Amortization | -2.41% | -4.10% | -4.14% | 6.64% | 6.23% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -69.59% | 151.47% | -46.44% | 219.90% | 2,081.65% |
| Change in Net Operating Assets | -337.17% | -127.55% | 87.18% | 326.21% | -63.03% |
| Cash from Operations | -52.41% | -0.25% | 16.52% | 11.63% | -40.29% |
| Capital Expenditure | -- | -- | -- | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | 100.00% |
| Total Debt Issued | -100.00% | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -17.31% | 553.80% | -6.31% | -96.76% | 19,193.33% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -100.00% | -- |
| Cash from Financing | -68.88% | 3,675.95% | -6.31% | -96.76% | 51,156.67% |
| Foreign Exchange rate Adjustments | 8.33% | 280.49% | -- | -- | 1,700.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -106.27% | 135.15% | 121.92% | -194.92% | 555.03% |